Apple (AAPL) was downgraded to equal-weight at Barclays. $117 price target. There appears to be limited near-term upside in the company's earnings potential, Barclays said.
Aetna (AET) was downgraded to market perform at Leerink. $135 price target. The Humana deal stalled and the company is facing challenges in all business segments, Leerink said.
DineEquity (DIN) was downgraded to neutral from buy at Nomura. $77 price target. Earnings estimates were also cut, given lower sales trends, Nomura reasoned.
Performance Food (PFGC) was downgraded to equal-weight from overweight at Barclays. $25 price target. Fundamentals have stalled and cash flow will likely decline in the first half of the year, Barclays said.
Silgan (SLGN) was upgraded to outperform at BMO Capital. $65 price target. The Westrock deal appears to make both strategic and financial sense, BMO said.